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PCardiac Resynchronization Therapy
Heart Failure Decompensation and
All-Cause Mortality in Relation to Percent
Biventricular Pacing in Patients With Heart Failure
Is a Goal of 100% Biventricular Pacing Necessary?
Bruce A. Koplan, MD, MPH,* Andrew J. Kaplan, MD,† Stan Weiner, MD,‡ Paul W. Jones, MS,§
Milan Seth, MS, Shelly A. Christman, PHD§
Boston, Massachusetts; Mesa, Arizona; Tyler, Texas; and St. Paul and Brooklyn Park, Minnesota
Objectives The goal of this analysis was to determine the appropriate biventricular pacing target in patients with heart fail-
ure (HF).
Background Cardiac resynchronization therapy (CRT) decreases the risk of death and HF hospitalization. However, the appro-
priate amount of biventricular pacing is ill-defined.
Methods Mortality and HF hospitalization data from patients undergoing CRT in 2 trials (CRT RENEWAL [Cardiac Resyn-
chronization Therapy Registry Evaluating Patient Response with RENEWAL Family Devices] and REFLEx
[ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance Study]; n  1,812) were analyzed in a
post-hoc fashion. Subjects were grouped based on percent biventricular pacing quartiles with the use of Kaplan-
Meier survival analysis.
Results Subjects were age 72  11 years; 72% were men and 67% had coronary artery disease. Subjects paced 93% to
100% (quartiles 2 to 4) had a 44% reduction in hazard of an event compared with subjects paced 0% to 92%
(quartile 1; hazard ratio [HR]: 0.56, p  0.00001). Subjects paced 98% to 99% (quartile 3) had similar out-
comes as subjects paced 93% to 97% (quartile 2; HR: 0.97, p  0.82). Subjects paced 100% (quartile 4) had
similar outcomes as subjects paced 98% to 99% (HR: 0.78, p  0.17). There was a significant interaction be-
tween a history of atrial arrhythmia and percent pacing. Subjects with a history of atrial arrhythmia were more
likely to be paced 92% (p  0.001).
Conclusions For CRT patients in this retrospective analysis, the greatest magnitude of benefit was observed with 92%
biventricular pacing. (J Am Coll Cardiol 2009;53:355–60) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.043a
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wardiac resynchronization therapy (CRT) has been shown
o reduce heart failure (HF) decompensation and hospital-
zation rates and to improve exercise tolerance and left
entricular remodeling in subjects with moderate or severe
ymptomatic HF and evidence of dyssynchrony (1–6). It is
enerally believed that near-maximal biventricular pacing is
ecessary to assure optimal CRT response. One study used
rom the *Brigham and Women’s Hospital, Boston, Massachusetts; †Banner Heart
ospital, Mesa, Arizona; ‡Tyler Cardiovascular Consultants, Tyler, Texas; §Boston
cientific Corporation, St. Paul, Minnesota; and The Integra Group, Brooklyn Park,
innesota. Dr. Koplan is a consultant for Boston Scientific and St. Jude Medical and
as received speaking honoraria from Medtronic, Boston Scientific, and St. Jude
edical. Dr. Kaplan is a consultant for Boston Scientific and has received speaking
onoraria for Boston Scientific. Drs. Weiner and Seth are consultants for Boston
cientific. Drs. Jones and Christman are employees and stockholders of Boston
cientific.p
Manuscript received July 8, 2008; revised manuscript received September 8, 2008,
ccepted September 25, 2008.n arbitrary cutoff rate of biventricular pacing 85% of
acing time (7). However, the appropriate target for biven-
ricular pacing percentage is ill-defined. In some patients
ith brisk atrioventricular nodal conduction either in sinus
hythm or while in atrial fibrillation (AF), 100% pacing can
e challenging to achieve. This challenge is important,
See page 361
ecause AF frequently is associated with HF (8) and has
een shown to be an independent predictor of morbidity
nd mortality (9,10). Whether incremental benefit occurs
eyond a pacing percentage of 85%, 90%, or greater is
ncertain. We sought to determine whether or not incre-
ental benefit in mortality and HF hospitalization occurs
ith pacing at or near 100% compared with lower pacing
ercentage rates in a large cohort of patients.
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Subjects. All-cause mortality
and HF hospitalization data
from 1,812 subjects undergo-
ing CRT in 2 trials, the CRT
RENEWAL (Cardiac Resyn-
chronization Therapy Registry
Evaluating Patient Response with
RENEWAL Family Devices)
(11) and REFLEx (ENDOTAK
RELIANCE G Evaluation of
Handling and Electrical Perfor-
mance) (12), were analyzed in a
post-hoc fashion. Subjects en-
rolled in the 2 trials met current
device indications and were im-
planted with a CRT defibrillator.
ubjects were followed up at implant, wound check, and 3,
, and 12 months after implant.
At each follow-up visit, subjects were asked whether they
ad been seen for an HF hospitalization since their last visit
nd the date of this event. To be considered an HF
ospitalization, a subject must have been hospitalized for
24 h with worsening of symptoms and had 1 or more
ntensive treatments (intravenous [IV] diuretics, IV nesirit-
de, IV inotropes, placement on transplant list) for HF.
evice interrogation also was performed at each visit.
tatistical analyses. Subjects were grouped based on life-
ime biventricular pacing percentages (total paced left ven-
ricular beats divided by total paced  sensed beats over the
ifetime of the device) with the use of Kaplan-Meier survival
nalysis with a combined end point of HF hospitalization
nd all-cause mortality. Baseline demographics were evalu-
ted using summary statistics. The Cochrane-Armitage test
or trend in proportions was used to evaluate a trend in the
vent rate (events per follow-up month) with increased
iventricular pacing. Multivariate Cox proportional hazards
urvival models also were used to evaluate lifetime biven-
ricular pacing adjusting for a number of baseline clinical
nd demographic factors as a predictor of the time to the
mplant Demographics
Table 1 Implant Demographics
Male, n (%) 1,298 (71.6)
Age (mean yrs  SD) 72 11
NYHA functional class, n (%)
II 210 (11.6)
III 1,390 (76.7)
IV 163 (9)
Unknown 49 (2.7)
Diabetes, n (%) 570 (31.5)
Coronary artery disease, n (%) 1,210 (66.8)
Hypertension, n (%) 1,050 (58.0)
Myocardial infarction, n (%) 880 (48.6)
History of atrial arrhythmia, n (%) 617 (34.1)
Abbreviations
and Acronyms
AF  atrial fibrillation
ATR  atrial tachycardia
response
CRT  cardiac
resynchronization therapy
HF  heart failure
HR  hazard ratio
IV  intravenous
NYHA  New York Heart
Association
Q  quartile
VRR  ventricular rate
regulationwYHA  New York Heart Association.ombined end point. A p value 0.05 was considered
tatistically significant without adjustment for multiple
omparisons. These analyses were performed using the R
tatistical software package version 2.5.1 (13).
A secondary analysis also was performed with the recent
ercent time in atrial tachycardia response (ATR) mode
witch and recent percent biventricular pacing values col-
ected at in-clinic visits throughout follow-up as predictors
f the time to the combined end point event. For this
nalysis, we fitted a Cox proportional hazards survival model
ith these variables as time-dependent covariates, while
ontinuing to adjust for baseline predictors as fixed covari-
tes. This analysis was conducted to address concern over
otential discrepancies between the lifetime pacing percent
or the patient and pacing in the time interval during which
n event occurred, as well as the potential impact of the
evelopment of AF (as indicated by the ATR mode switch
ercent) over the course of follow up. This analysis was
erformed using SAS statistical software version 9.1 (SAS
nstitute, Cary, North Carolina).
esults
emographics. Subjects enrolled in the 2 studies were
ypical of the HF population enrolled in large clinical trials:
high percentage of men, most with New York Heart
ssociation (NYHA) functional class III HF, a majority
ith a history of coronary artery disease, and approximately
5% with a history of atrial arrhythmia (included a history of
trial fibrillation, atrial flutter, atrial tachycardia) (Table 1).
his history of atrial arrhythmia was based on answers to a
uestionnaire in both studies. Median follow-up was 10.7
onths.
utcomes. Figure 1 illustrates the number of subjects that
Figure 1 Biventricular Pacing Percentage in All Patientsere biventricularly paced at each percentage. A multivari-
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January 27, 2009:355–60 Is a Goal of 100% Biventricular Pacing Necessary?te Cox model was used to identify predictors of death or
F hospitalization (Table 2). A history of diabetes (hazard
atio [HR]: 1.43, p  0.002), coronary artery disease (HR:
.55, p  0.002), and atrial arrhythmia (HR: 1.34, p 
.01), and worse NYHA functional class (II vs. III, HR:
.66, p  0.042; III vs. IV, HR: 0.55, p  0.001) had a
reater hazard of experiencing death or HF hospitalization.
ecause data were combined from 2 studies, after adjusting
or covariates, the study was put into the Cox proportional
azards survival model and was found to not be a predictor
f HF hospitalization and all-cause mortality (p  0.35).
Subjects were divided into quartiles based on percent
iventricular pacing (Fig. 2): Quartile (Q)1  0% to 92%
n 467), Q2 93% to 97% (n 474), Q3 98% to 99%
n  509), and Q4  100% (n  362). Subjects paced in
2 to Q4 had a 44% reduction in hazard of an event
ompared with subjects paced in Q1 (HR: 0.56, p 
.00001). Subjects paced in Q2 had a 38% reduction in
azard of an event compared to subjects paced in Q1 (HR:
.62, p  0.0013). Subjects paced in Q3 had similar
utcomes as subjects paced in Q2 (HR: 0.97, p  0.82).
ubjects paced in Q4 had similar outcomes as subjects paced
3 (HR: 0.78, p 0.17). The test for trend for fewer events
s pacing increased was highly significant (p  0.00001).
Subjects paced in Q1 were more likely to be men (p 
.006) and have a history of atrial arrhythmia (p  0.001).
owever, patients paced in Q1 were less likely to have a
istory of diabetes (p  0.008) or hypertension (p  0.01)
Table 3).
On the basis of the likelihood ratio test, it was deter-
ined that a history of atrial arrhythmia had a significant
nteraction with pacing percentage. Therefore, the interac-
ion term was included, modeling the impact of pacing for
ubjects with a history of atrial arrhythmia and subjects
ithout a history of atrial arrhythmia separately.
ubjects with no history of atrial arrhythmia. In subjects
ith no history of atrial arrhythmia (Fig. 3A), the model
emonstrates incremental benefit in the combined end
oint with increasing levels of pacing percentage, even with
reater pacing percentages. Subjects paced in Q2 to Q4
ultivariate Cox Proportionalazards Survival M del Identifyingred ctors of Death or HF Hosp talization
Table 2
Multivariate Cox Proportional
Hazards Survival Model Identifying
Predictors of Death or HF Hospitalization
HR p Value
Male vs. female 0.81 0.10
Diabetes 1.43 0.002
History of coronary artery disease 1.55 0.002
History of atrial arrhythmia 1.34 0.010
History of myocardial infarction 1.08 0.54
Hypertension 0.95 0.68
NYHA functional class II vs. III 0.66 0.042
NYHA functional class III vs. IV 0.55 0.001
Pacing 92% vs. 92% 0.56 0.00001
F  heart failure; HR  hazard ratio; other abbreviation as in Table 1.93% to 100%) had a 32% reduction in hazard of an eventompared with subjects paced in Q1 (0% to 92%; HR: 0.68,
 0.02). Subjects paced in Q3 to Q4 (98% to 100%) had
34% reduction in hazard of an event compared with
ubjects paced in Q2 (93% to 97%; HR: 0.66, p  0.01).
nd, subjects paced in Q4 (100%) had a 34% reduction in
azard of an event compared to subjects paced in Q2 to Q3
93% to 99%; HR: 0.66, p  0.04). The test for trend for
ewer events as pacing increased was also significant (p 
.002).
ubjects with a history of atrial arrhythmia. In subjects
ith a history of atrial arrhythmia (Fig. 3B), subjects paced
2 to Q4 (93% to 100%) had a 56% reduction in hazard of
n event compared with subjects paced in Q1 (0% to 92%;
R: 0.44, p  0.00001). Subjects paced in Q2 had a 65%
eduction in hazard of an event compared with subjects
aced in Q1 (HR: 0.35, p  0.001). Beyond this, however,
here did not appear to be incremental benefit as percent
acing increased with regard to the combined end point.
he test for trend for fewer events as pacing increased was
ignificant (p  0.002).
ubjects with atrial arrhythmia during follow-up. Because of
he interaction between history of atrial arrhythmia and
acing percentage, the actual time spent in ATR mode
witch (as a proxy for time spent in AF) was evaluated. The
5th percentile for ATR mode switch percentage was 9%.
here were 138 (7.6%) patients that had lifetime ATR
ode switch percent (as measured at the last follow-up visit
or the lifetime of the device) 9%. Mode switch percent-
ges, as well as biventricular pacing percentages, also were
xamined at each in-clinic visit (recent ATR mode switch,
ecent biventricular pacing percentage). One hundred
eventy-six (9.7%) patients had a recent ATR mode switch
9%. Recent ATR mode switch percentage 9% was not a
redictor of the combined end point of HF hospitalization
nd all-cause mortality after adjusting for baseline covariates
Figure 2 Survival Free From Heart Failure
Hospitalization and All-Cause Mortality in All Patients
Quartile (Q)2 versus Q1, hazard ratio (HR): 0.62, p  0.0013; Q3 versus Q2,
HR: 0.97, p  0.82; Q4 versus Q3, HR: 0.78, p  0.17; Q2 to Q4 versus Q1,
HR: 0.56, p  0.00001.
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Values are n (%) unless otherwise specified.
CAD  coronary artery disease; NYHA  New York Heart Association; Q  quartile.
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Is a Goal of 100% Biventricular Pacing Necessary? January 27, 2009:355–60n a Cox model analysis with time-dependent covariates
14). However, patients with a lifetime ATR mode switch
ercentage 9% were at increased risk of HF hospitaliza-
ion or all-cause mortality compared with subjects with
ifetime ATR mode switch 9% (HR: 1.51, p  0.018).
fter adjusting for baseline covariates, including history of
trial arrhythmia, as well as lifetime and recent biventricular
acing percentage, lifetime ATR mode switch 9% was no
onger significant. Interestingly, both recent (HR: 1.406,
 0.01) and lifetime biventricular pacing percentages
92% (HR: 1.424, p  0.0087) were significant and
emained significant even when both were included in a
ultivariate model adjusting for baseline covariates and
ifetime ATR mode switch dichotomized at 9%.
We also examined recent and lifetime ATR mode switch
0%. There were 261 (14.4%) patients with lifetime ATR
ode switch 0% and 376 (20.8%) patients with recent
TR mode switch 0%. Similar to the results in patients
ith ATR mode switch 9%, only lifetime ATR mode
witch was associated with the combined end point of HF
ospitalization and all-cause mortality (HR: 1.32, p  0.05).
hy some subjects do not pace >92%. Subjects paced
92% had more LV lead-related adverse events (p  0.001),
ere more likely to have a history of atrial arrhythmia (p 
.001), and were less likely to have device algorithms to
ncrease ventricular pacing percentage during atrial arrhyth-
ias, such as ventricular rate regulation (VRR), programmed
n (p  0.001). Subjects with lower percent pacing also had a
reater programmed mean fixed atrioventricular (AV) delay
p  0.001) and a greater mean maximum (p  0.003) and
inimum (p  0.001) dynamic AV delay than subjects that
ere paced 92% of the time (Table 4). After adjusting for
aseline covariates and lifetime biventricular pacing quartile,
rogramming mode did not have an impact on whether
atients were paced92%. Of the 1,812 patients, 1,387 (77%)
ere programmed DDD and 172 (9%) were programmed
VI at all follow-up visits. The remaining 14% of patients did
ot have a consistently programmed mode throughout follow-
92%
nts Paced >92%
Q3
98% to 99%
(n  509)
Q4
100%
(n  362)
p Value for
Q1 vs. Q2 to Q4
365 (71.1) 230 (63.5) 0.006
178 (35.0) 111 (30.7) 0.008
354 (69.6) 219 (60.5) 0.114
148 (29.1) 108 (29.8) 0.001
258 (50.7) 157 (43.4) 0.07
318 (62.5) 204 (56.4) 0.01
NYHA overall chi-square 0.07
52 (10.2) 43 (11.9)
388 (76.2) 280 (77.4)
64 (12.6) 30 (8.3)Figure 3
Survival Free From HF Hospitalization and All-Cause
Mortality in Patients With No History of Atrial Arrhythmia
and Patients With History of Atrial Arrhythmia
(A) Survival free from heart failure (HF) hospitalization and all-cause mortality
in patients with no history of atrial arrhythmia. Q2 to Q4 versus Q1, HR: 0.68,
p  0.02; Q3 to Q4 versus Q2, HR: 0.66, p  0.01; Q4 versus Q2 to Q3, HR:
0.66, p  0.04. (B) Survival free from heart failure hospitalization and all-
cause mortality in patients with a history of atrial arrhythmia. Q2 to Q4 versus
Q1, HR: 0.44, p  0.00001; Q2 versus Q1, HR: 0.34, p  0.001. Abbrevia-
tions as in Figure 2.aseline Covariates for Patients Paced <92% Versus Patients Paced >
Table 3 Baseline Covariates for Patients Paced <92% Versus Patie
Q1
0% to 92%
(n  467)
Q2
93% to 97%
(n  474)
Sex, n (% male) 359 (76.9) 344 (72.6)
Diabetes 124 (26.6) 157 (33.1)
History of CAD 298 (63.8) 339 (71.5)
History of atrial arrhythmia 200 (42.8) 161 (34.0)
History of myocardial infarction 210 (45.0) 255 (53.8)
Hypertension 247 (52.9) 281 (59.3)
NYHA functional class
II 60 (12.9) 55 (11.6)
III 348 (74.5) 374 (78.9)
IV 34 (7.3) 35 (7.4)p, but it was limited to DDD, VVI, DDI, or VDD.
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January 27, 2009:355–60 Is a Goal of 100% Biventricular Pacing Necessary?Interestingly, 54% of patients paced 92% improved by
t least 1 NHYA functional class between implant and 6
onths, whereas 46% of patients paced 92% improved by
t least 1 NYHA functional class (p  0.014).
iscussion
his large retrospective analysis is the first to investigate
ppropriate biventricular pacing percentage in patients with
F receiving CRT. In our analysis of 1,800 patients, the
reatest magnitude of reduction in HF hospitalization and
ll-cause mortality was observed with a biventricular pacing
utoff of 92%. It is interesting that in our analysis, the
atients paced 92% had worse outcomes and were less
ikely to improve 1 NYHA functional class from implant to
months than patients paced 92%. Previous studies have
hown that approximately 30% of patients treated with
RT do not respond to treatment (4,15).
Because AF is often associated with HF and is an
ndependent risk factor for morbidity and mortality (9,10)
nd because AF can reduce the percentage of ventricular
acing, we examined the effect that a history of atrial
rrhythmia at implant had on the outcome of mortality and
F hospitalization. It is widely perceived that the combi-
ation of AF and HF results in a worse prognosis than
ither by itself. And, indeed, we did find a significant
nteraction between a history atrial arrhythmia at implant
nd percent biventricular pacing with respect to the com-
ined end point of all-cause mortality and HF hospitaliza-
ion in this retrospective analysis. In patients with no history
f atrial arrhythmia, a greater pacing percentage (98% or
reater) showed a significant incremental reduction in
ortality and HF hospitalization compared with pacing
3% to 97%. However, for patients with a history of atrial
rrhythmia, pacing incrementally 92% (i.e., 98% to 99%
s. 93% to 97% and 100% vs. 98% to 99%) did not further
educe the risk of HF hospitalization and all-cause mortality.
Because the occurrence of AF is an independent predictor
f morbidity and mortality (9,10), we also examined the
ercentage of time a subject spent in ATR mode switch
ecause pacemakers often are programmed to mode-switch
n the presence of atrial arrhythmias (16). Interestingly,
hy Do Some Subjects Pace <92%?
Table 4 Why Do Some Subjects Pace <92%?
Q1
0% to 92%
(n  467)
Q2
93% to
(n  4
Patients with LV-lead related AEs 31 (6.64%) 12 (2
History of atrial arrhythmia 200 (42.8%) 161 (3
VRR “on” 327 (70.02%) 402 (8
Mean fixed AV delay 133.32 (n 271) 121.84 (n
Median sensed AV offset 30 ms 30
Mean of maximum dynamic AV delay 141.71 (n 82) 131.29 (n
Mean of minimum dynamic AV delay 101.10 90.3
E  adverse events; AV  atrioventricular; LV  left ventricular; Q  quartile; VRR  ventricularubjects with lifetime ATR mode switch (as measured at tnal follow-up visit) 9% or 0% were at increased risk of
ll-cause mortality or HF hospitalization, but ATR mode
witch9% or0% measured at the most recent follow-up
isit was not associated with worse outcomes. These data are
imilar to those recently reported by Gilliam et al. (17), who
ound that patients with chronic high-rate atrial arrhythmia
urden (possible marker for AF) have a greater incidence of
F decompensation but that high-rate atrial burden does
ot necessarily increase prior to HF decompensation. Our
nalyses clearly indicate that AF occurrence alone does not
ccount for the increased risk of HF hospitalization and
ll-cause mortality associated with lower biventricular pac-
ng percentages.
To address the concern of collecting the predictor (biven-
ricular pacing percentage) after the outcome (HF hospital-
zation or all-cause mortality), we examined biventricular
acing percentage at each follow-up visit (recent biventricu-
ar pacing percentage). Unlike ATR mode switch, where
ecent ATR mode switch was not a predictor of HF
ospitalization or all-cause mortality, recent biventricular
acing percentages 92% were significant predictors of the
ombined end point, again highlighting the implication that
ower biventricular pacing percentages result in worse out-
omes, which also may be a clinical concern if a patient’s
iventricular pacing percentage suddenly decreases.
Although it would seem practical to program devices to
chieve maximal percent pacing when CRT therapy is
rovided, our findings have certain clinical implications. For
atients in whom 100% pacing is not easily achieved because
f enhanced AV nodal conduction either in sinus rhythm or
hile in atrial fibrillation, our analysis provides guidance
egarding a reasonable goal to try to attain. Our results could
lso provide appropriate desired percent pacing cutoffs for
uture research.
mplications for increasing biventricular pacing. We
ound a statistically lower utilization rate of the VRR
lgorithm in patients with 0% to 92% pacing compared with
atients paced 93% to 100%, suggesting that a more
ggressive use of the VRR algorithm could increase the
ercent biventricular pacing in patients that experience atrial
rrhythmias. In addition, lowering AV delays also increases
Q3
98% to 99%
(n  509)
Q4
100%
(n  362)
p Value for
Q1 vs. Q2 to Q4
5 (0.98%) 10 (2.76%) 0.001
148 (29.0%) 108 (30.0%) 0.001
) 446 (87.62%) 320 (88.4%) 0.001
1) 121.83 (n 367) 121.83 (n 246) 0.001
30 ms 30 ms
) 122.91 (n 103) 122.10 (n 81) 0.003
86.41 88.40 0.001
gulation.97%
74)
.53%)
4.0%)
4.81%
 33
ms
 93
2he percentage of biventricular pacing.
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Is a Goal of 100% Biventricular Pacing Necessary? January 27, 2009:355–60tudy limitations. The limitations of our analysis include
hat it was a retrospective cohort analysis. Although we
ccounted for important covariates, like atrial fibrillation, we
annot conclusively determine the independent effects of
F and biventricular pacing percentage. In addition, the
xact time-course of changes in pacing percentage, occur-
ence of AF and their relationship to an event was not
valuated. Finally, confounders to pacing counters like
usion/pseudofusion could not be assessed because the
nformation required was not collected in these 2 studies.
arger prospective studies are required to confirm our
ndings.
onclusions
or patients undergoing CRT in this retrospective analysis,
he greatest magnitude of benefit was observed with 92%
iventricular pacing. Although percent biventricular pacing
hould be maximized whenever possible, the data in this
etrospective analysis provide guidance with respect to the
ercent pacing that should be targeted in patients whom
00% biventricular pacing is difficult to achieve.
eprint requests and correspondence: Dr. Bruce A. Koplan,
righam and Women’s Hospital, Cardiovascular Division, 75
rancis Street, Tower 3A, Boston, Massachusetts 02115. E-mail:
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